Scholarlink

<p>Oligomerization of proteoforms produces functional protein complexes. Characterization of these assemblies within cells is critical to understanding the molecular mechanisms involved in disease and to designing effective drugs. Here we present a native top-down proteomics (nTDP) strategy to identify protein assemblies (≤70 kDa) in breast cancer cells and in cells that overexpress epidermal growth factor receptor (EGFR), which serves as a resistance model of estrogen receptor-alpha (ER)-targeted therapies. This nTDP approach identified ~104 complexoforms from 17 protein complexes, which revealed several molecular features of the breast cancer proteome, including EGFR-induced dissociation of nuclear transport factor 2 (NUTF2) assemblies that modulate ER activity. We found that the K4 and K55 post-translational modification sites discovered with nTDP differentially impact the effects of NUTF2 on the inhibition of the ER signaling pathway. The characterization of endogenous proteoform–proteoform/ligand interactions revealed the molecular diversity of complexoforms and their role in breast cancer growth.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Native top-down proteomics enables discovery in endocrine-resistant breast cancer

  • 期刊论文

  • 发表日期：

    2025年4月4日

查看全文
  • Fabio P. Gomes,
  • Kenneth R. Durbin,
  • Kevin Schauer,
  • Jerome C. Nwachukwu,
  • Robin R. Kobylski,
  • Jacqline W. Njeri,
  • Ciaran P. Seath,
  • Anthony J. Saviola,
  • Daniel B. McClatchy,
  • Jolene K. Diedrich,
  • Patrick T. Garrett,
  • Alexandra B. Papa,
  • Ianis Ciolacu,
  • Neil L. Kelleher,
  • Kendall W. Nettles,
  • John R. Yates III

摘要

Oligomerization of proteoforms produces functional protein complexes. Characterization of these assemblies within cells is critical to understanding the molecular mechanisms involved in disease and to designing effective drugs. Here we present a native top-down proteomics (nTDP) strategy to identify protein assemblies (≤70 kDa) in breast cancer cells and in cells that overexpress epidermal growth factor receptor (EGFR), which serves as a resistance model of estrogen receptor-alpha (ER)-targeted therapies. This nTDP approach identified ~104 complexoforms from 17 protein complexes, which revealed several molecular features of the breast cancer proteome, including EGFR-induced dissociation of nuclear transport factor 2 (NUTF2) assemblies that modulate ER activity. We found that the K4 and K55 post-translational modification sites discovered with nTDP differentially impact the effects of NUTF2 on the inhibition of the ER signaling pathway. The characterization of endogenous proteoform–proteoform/ligand interactions revealed the molecular diversity of complexoforms and their role in breast cancer growth.